Security Stocks; Tobin Smith of NBT Equity Group Interviews Visualant (OTCBB:VSUL) CEO

SEATTLE - April 7, 2011 (Investorideas.com Defense Newswire) - Visualant, Inc. (OTCBB: VSUL), a pioneer provider of industry-leading color based identification and diagnostic solutions, an emerging leader in security and authentication systems technology and distributor of a wide variety of security solutions through its wholly-owned subsidiary, TransTech Systems, Inc., announced today that Tobin Smith of NBT Equity Research LLC has released an interview with Visualant Chairman and Chief Executive Officer Ron Erickson. The interview can be accessed through the Visualant website at www.visualant.net or on the NBT Equity Research website at http://nbtequitiesresearch.com/company/visualant-vsul/nbt-tv.

NBT Equity Research LLC is a member of the NBT Equity Group LLC. They were founded by well known research analyst Tobin Smith. Tobin Smith is a contributing market analyst for Fox News Channel and a regular panelist on its highly rated "Bulls & Bears" weekly investment program.
On January 24, 2011, Tobin Smith issued a research report on Visualant which he supplemented on February 11, 2011. Both research reports can be accessed through the Visualant website at www.visualant.net.
About Visualant, Inc.
Visualant, Inc. (OTCBB: VSUL) develops low-cost, high speed, light-based security and quality control solutions for use in homeland security, anti-counterfeiting, forgery/fraud prevention, brand protection and process control applications. Our patent-pending technology uses controlled illumination with specific bands of light, to establish a unique spectral signature for both individual and classes of items. When matched against existing databases, these spectral signatures allow precise identification and authentication of any item or substance. This breakthrough optical sensing and data capture technology is called Spectral Pattern Matching ("SPM"). SPM technology can be miniaturized and is easily integrated into a variety of hand-held or fixed mount configurations, and can be combined in the same package as a bar-code or biometric scanner.
Through its wholly owned subsidiary, TransTech Systems, Inc., the Company provides security and authentication solutions to security and law enforcement markets throughout the United States.
Contact:
Visualant, Inc.:
Lynn Felsinger
206 903 1351
Lynn@visualant.net
Investor Relations
Paul DeRiso
Core Consulting Group
925-465-6088
paul@coreconsultingroup.com

Visualant, Inc. (OTCBB:VSUL) Featured showcase company on Investorideas.com and related security portals and blogs
Visit the showcase page: http://www.investorideas.com/CO/VSUL/
Disclaimer: Visualant, Inc. (OTCBB:VSUL) is a paid advertising featured showcase company on Investorideas.com and related security portals and blogs. (2500 per month)

Security Stocks; TransTech Systems, a Subsidiary of Visualant (OTCBB:VSUL), to Distribute Farpointe Data's Access Card Programmer

SEATTLE - April 6, 2011 (Investorideas.com Defense Newswire) - Visualant, Inc. (OTCBB: VSUL), a pioneer provider of industry-leading color based identification and diagnostic solutions, an emerging leader in security and authentication systems technology and distributor of a wide variety of security solutions through its wholly-owned subsidiary, TransTech Systems, Inc., is pleased to announce that TransTech Systems has been chosen to distribute Farpointe Data's new field programmer for access control credentials.

This week Farpointe Data has launched their new CoG-1000 Cards on the Go™ Multi-Technology Field Programmer. Farpointe Data manufactures access control card readers and credentials for many of the leading building access control systems in the market today. TransTech Systems, Farpointe Data's key distributor in the Americas, has been chosen to market the new CoG-1000 field access card programmer.
Scott Lindley, President of Farpointe Data, said, "Cards on the Go™ is a move to address a number of concerns of our customers, including the compressing of lead times and inventories of access credentials, while still providing the security. We are pleased to have TransTech Systems supporting their significant dealer channel with the new Cards on the Go™ solution."
Cards on the Go™ is a stand-alone access control credential programmer designed to give security access control professionals and system integrators the ability to program both proximity and contactless smartcard credentials. It is capable of producing one card at a time, as well as producing larger runs. The Cards on the Go™ solution includes a USB-based desktop programmer, a USB cable, programming software and 100 preloaded programming tokens. Various add-ons and enhancements to the Cards on the Go™ solution are planned for release during 2011. Additional tokens can be ordered through TransTech as well.
"Adding Farpointe Data's technology to our offering brought a very strong and reliable product line to our customer base," said Jeff Kruse, TransTech Systems General Manager. "The Cards on the Go™ solution is fairly unique in the current marketplace and should provide real opportunity for our channel partners."
About Visualant, Inc.
Visualant, Inc. (OTCBB: VSUL) develops low-cost, high speed, light-based security and quality control solutions for use in homeland security, anti-counterfeiting, forgery/fraud prevention, brand protection and process control applications. Our patent-pending technology uses controlled illumination with specific bands of light, to establish a unique spectral signature for both individual and classes of items. When matched against existing databases, these spectral signatures allow precise identification and authentication of any item or substance. This breakthrough optical sensing and data capture technology is called Spectral Pattern Matching ("SPM"). SPM technology can be miniaturized and is easily integrated into a variety of hand-held or fixed mount configurations, and can be combined in the same package as a bar-code or biometric scanner.
Through its wholly owned subsidiary, TransTech Systems, Inc., the Company provides security and authentication solutions to security and law enforcement markets throughout the United States.
Contact:
Visualant, Inc.:
Lynn Felsinger
206 903 1351
Lynn@visualant.net
Investor Relations
Paul DeRiso
Core Consulting Group
925-465-6088
paul@coreconsultingroup.com

Visualant, Inc. (OTCBB:VSUL) Featured showcase company on Investorideas.com and related security portals and blogs
Visit the showcase page: http://www.investorideas.com/CO/VSUL/
Disclaimer: Visualant, Inc. (OTCBB:VSUL) is a paid advertising featured showcase company on Investorideas.com and related security portals and blogs. (2500 per month)

Biotech/Biodefense Stock News; Aethlon Medical (OTCBB: AEMD) Releases Shareholder Letter

SAN DIEGO - April 6, 2011 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB: AEMD) disclosed today that its Chairman and CEO, James A. Joyce has issued the following letter to shareholders.

To our Shareholders:
On April 1st, we submitted a contract response to the Defense Advanced Research Projects Agency (DARPA) related to the Dialysis Like Therapeutics (DLT) program referenced in my last shareholder letter. In our submission, we proposed to leverage our technology platform to deliver a dialysis-like therapy that would address precursors to sepsis, including bacterial toxins, viral pathogens, and disease enhancing particles transported by exosomes. We believe our proposal meets goals underlying the DLT program as the resulting device would target to reduce the occurrence of sepsis and would provide decision-free and life saving medical care for the wounded warfighter. Additionally, we introduced an innovative strategy to deliver our dialysis-like therapy without the need for anticoagulants, as well as a novel approach to selectively clear whole bacteria from circulation.
If selected for an award, several larger organizations and industry thought leaders have agreed to partner with us to advance our program proposals. It is anticipated that the DLT program awards will be announced in the next 120 days. We are now collaborating with our advisors to determine the next contract or grant opportunity to pursue. Beyond non-dilutive bioterror and pandemic threat funding opportunities, we are also evaluating potential responses to new government programs in Hepatitis-C, HIV, and Cancer.
In addition to navigating government funding opportunities, we are actively advancing research and clinical initiatives in both infectious disease and cancer. On the clinical front, I am pleased to disclose that we our close to submitting our updated IDE to the FDA. The goal of our submission is approval from the FDA to initiate Hemopurifier� human studies in the United States. Details regarding our FDA communications and clinical site locations can be expected through forthcoming news disclosures.
In regards to our HCV treatment study in India, we initiated treatment of our first patient at the Medanta Medicity Institute, which was observed by our President, Rod Kenley. In previous studies, we demonstrated significant viral load reductions in health compromised dialysis patients that were infected with either HCV or HIV. In this study, we are leveraging those results to demonstrate that our Hemopurifier� can accelerate viral load reduction when administered to non-dialysis patients in combination with drug therapy. Based on a prior clinical validation, we are confident in our capabilities and recognize the potential significance of our Hemopurifier� as viral load depletion rates in the earliest stages of therapy are considered predictive of patients who achieve long-term clinical benefit. In the treatment of our first patient, it was recognized early on that that we needed to modify our protocol to administer anticoagulants in dosages specific to our therapy, and not in amounts normally administered to dialysis patients. Regardless, there was no harm to this patient, although the anticoagulant miscalculation did not allow him to successfully complete his entire treatment. While causing a delay of several weeks, our protocol has been formally amended and we are now ramping up patient enrollment. We are also seeking to open up our study to those residing outside of India, based on worldwide inquiries from infected individuals.
In closing, I also wish to disclose that Jeff Richardson has agreed to rejoin our team on a part-time basis. While you may or may not recall Jeff, he was responsible for originating national news coverage our technology through multiple media outlets, including Popular Science, CNN, and Readers Digest. As the former communications director at Amgen, Jeff provides tremendous insight on advancing the awareness of innovative medical therapies through the national media.
On behalf of our dedicated team at Aethlon Medical, I thank you for your continued support.
Very truly yours,
James A. Joyce
Chairman, CEO
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the capability of the Hemopurifier� to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, including obtaining government grants, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the ability to achieve commercialization in India as a result of the proposed treatment program at Medanta, The Medicity Institute, whether successful or not, the ability of the Hemopurifier� to improve the efficacy of SOC therapy against HCV, the Company's ability to manufacture its products either internally or through outside companies and to create future generations of the Hemopurifier�, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
jps@aethlonmedical.com

AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock)
Effective March 15, 2011

Security Stocks; Visualant (OTCBB:VSUL) Spectral Pattern Matching Technology at International Security Conference & Exposition

SEATTLE - April 5, 2011 (Investorideas.com Defense Newswire) - Visualant, Inc. (OTCBB: VSUL), a pioneer provider of industry-leading color based identification and diagnostic solutions and an emerging leader in security and authentication systems technology will be demonstrating its Spectral Pattern Matching (�SPM�) technology at the booth of its wholly-owned subsidiary, TransTech Systems, Inc., at the International Security Conference & Exposition from April 6-8, 2011 at the Sands Expo & Convention Center in Las Vegas, NV.

The International Security Conference & Exposition (ISC West) is one of the fastest growing tradeshows in North America according to the publication Tradeshow Week. With over 23,000 industry professionals and 14,600 security buyers, ISC West is certainly the nation's largest security event of the year. ISC West will be hosting education sessions from April 5-7, 2011 as well as the exposition from April 6-8, 2011. See www.iscwest.com for more information.
Visualant's SPM technology sees color, nature's fingerprint, at the photon level. The SPM technology sees color the counterfeiter cannot see and provides an extra level of security against hacking in the important world of authentication.
See the Visualant SPM technology at TransTech's booth #22129.
About Visualant, Inc.
Visualant, Inc. (OTCBB: VSUL) develops low-cost, high speed, light-based security and quality control solutions for use in homeland security, anti-counterfeiting, forgery/fraud prevention, brand protection and process control applications. Our patent-pending technology uses controlled illumination with specific bands of light, to establish a unique spectral signature for both individual and classes of items. When matched against existing databases, these spectral signatures allow precise identification and authentication of any item or substance. This breakthrough optical sensing and data capture technology is called Spectral Pattern Matching ("SPM"). SPM technology can be miniaturized and is easily integrated into a variety of hand-held or fixed mount configurations, and can be combined in the same package as a bar-code or biometric scanner.
Through its wholly owned subsidiary, TransTech Systems, Inc., the Company provides security and authentication solutions to security and law enforcement markets throughout the United States.
Contact:
Visualant, Inc.:
Lynn Felsinger
206 903 1351
Lynn@visualant.net
Investor Relations
Paul DeRiso
Core Consulting Group
925-465-6088
paul@coreconsultingroup.com

Visualant, Inc. (OTCBB:VSUL) Featured showcase company on Investorideas.com and related security portals and blogs
Visit the showcase page: http://www.investorideas.com/CO/VSUL/
Disclaimer: Visualant, Inc. (OTCBB:VSUL) is a paid advertising featured showcase company on Investorideas.com and related security portals and blogs. (2500 per month)

Security Stocks; TransTech Systems, a Subsidiary of Visualant (OTCBB:VSUL), to Exhibit at the International Security Conference & Exposition

SEATTLE - March 31, 2011 (Investorideas.com Defense Newswire) - Visualant, Inc. (OTCBB: VSUL), a pioneer provider of industry-leading color based identification and diagnostic solutions, an emerging leader in security and authentication systems technology and distributor of a wide variety of security solutions through its wholly-owned subsidiary, TransTech Systems, Inc., is pleased to announce that TransTech Systems will be exhibiting at the International Security Conference & Exposition from April 6-8, 2011 at the Sands Expo & Convention Center in Las Vegas, NV.

The International Security Conference & Exposition (ISC West) is one of the fastest growing tradeshows in North America according to the publication Tradeshow Week. With over 23,000 industry professionals and 14,600 security buyers, ISC West is certainly the nation's largest security event of the year. ISC West will be hosting education sessions from April 5-7, 2011 as well as the exposition from April 6-8, 2011. See www.iscwest.com for more information.
TransTech Systems (www.ttsys.com) will be exhibiting the latest in identification card printing and encoding systems and building access control products from manufacturers such as Evolis, NiSCA, FarPointe, and Datacard. TransTech also will be demonstrating the new Visualant Spectral Pattern Matching technology. See these and other popular security industry products on display in TransTech's booth #22129.
We will post this press release on the Visualant website at www.visualant.net. If we have an email address for you, we will send you a copy of our press releases electronically. We want to remind you that if you have not already done so, please enter your email and other information on the form on the website at: http://visualant.net/contactus.html.
About Visualant, Inc.
Visualant, Inc. (OTCBB: VSUL) develops low-cost, high speed, light-based security and quality control solutions for use in homeland security, anti-counterfeiting, forgery/fraud prevention, brand protection and process control applications. Our patent-pending technology uses controlled illumination with specific bands of light, to establish a unique spectral signature for both individual and classes of items. When matched against existing databases, these spectral signatures allow precise identification and authentication of any item or substance. This breakthrough optical sensing and data capture technology is called Spectral Pattern Matching ("SPM"). SPM technology can be miniaturized and is easily integrated into a variety of hand-held or fixed mount configurations, and can be combined in the same package as a bar-code or biometric scanner.
Through its wholly owned subsidiary, TransTech Systems, Inc., the Company provides security and authentication solutions to security and law enforcement markets throughout the United States.
Contact:
Visualant, Inc.:
Lynn Felsinger
206 903 1351
Lynn@visualant.net
Investor Relations
Paul DeRiso
Core Consulting Group
925-465-6088
paul@coreconsultingroup.com

Visualant, Inc. (OTCBB:VSUL) Featured showcase company on Investorideas.com and related security portals and blogs
Visit the showcase page: http://www.investorideas.com/CO/VSUL/
Disclaimer: Visualant, Inc. (OTCBB:VSUL) is a paid advertising featured showcase company on Investorideas.com and related security portals and blogs. (2500 per month)

Biodefense Stocks /Homeland Defense Stock Alert; Dynasil Corporation (NASDAQ GM: DYSL) trading at $6.26, up 2.50 (66.49%)

Radiation Fears and Biological Warfare Threats Raise Investor Interest in Biodefense Stocks;
(OTCBB: AEMD), (NASDAQ GM: DYSL), (NYSE Amex: PIP), (NasdaqGM: SIGA )

Point Roberts, WA- March 23, 2011 - Investorideas.com, a leader in investor sector research
including Homeland Defense and Biodefense Stocks issues a trading alert on the sector as
Dynasil Corporation of America(NasdaqGM: DYSL ) becomes the top gainer on the NASDAQ on
patent news for its radiation monitoring device.

Dynasil Corporation (NASDAQ GM:DYSL), announced today that its research division, Radiation
Monitoring Devices, Inc. (RMD), also of Watertown, was granted additional U.S. patent claims for
advances in a detector material capable of responding independently to both neutron and gamma
radiation. This advancement is of critical national importance because the most commonly
available technology for detecting neutrons in Homeland Security applications, specifically
neutron detectors based on gaseous Helium-3, is becoming impractical because of serious
limitations on the availability of this gas.



In a recent article on Daily Finance entitled “Inside Wall Street: Looking to the Bio-Defense
Sector as Nuclear Fears Mount”, notes - The sector attracted a lot of interest after 9/11 and a
number of companies emerged to develop protective biodefense drugs and products. But with the
waning of dark headlines about terrorist threats, investors have tended to put them on their low-
priority list.
That may be about to change

Full article : http://www.dailyfinance.com/story/stock-picks/inside-wall-street-looking-to-bio-defense-sector-as-
nuclear-fea/19880106/

Biodefense Stocks Sector Snapshot
Aethlon Medical (OTCBB: AEMD) trading at $0.14
Dynasil Corporation (NASDAQ GM: DYSL) trading at $6.26, up 2.50 (66.49%) 12:21PM EDT
Emergent Biosolutions, Inc. Com (NYSE: EBS ) trading at $23.53, down 0.04 (0.17%) 12:29PM
EDT
PharmAthene, Inc. (NYSE Amex: PIP) trading at $3.42, up 0.01 (0.29%) 12:27PM EDT
Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) trading at $0.32
Siga Technologies (NasdaqGM: SIGA ) trading at $12.27, up 0.25 (2.08%) 12:29PM EDT

Research more Biodfense stocks at Investorideas.com
http://www.investorideas.com/bds/stock_list.asp

Biodefense Company Snapshot

Aethlon Medical (OTCBB: AEMD)
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer.
Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in
disease diagnosis and monitoring.

Our Hemopurifier® is the first medical device to selectively target the removal of infectious
viruses and immunosuppressive proteins from the entire circulatory system. We recently
discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune
system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly
inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in
cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet
clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or
interaction risks to established and emerging treatment strategies.
More: www.aethlonmedical.com
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com

Visit the Aethlon Medical ( OTCBB:AEMD) showcase page on Investorideas.com
http://www.investorideas.com/CO/AEMD

Get added to the company’s news alerts:
http://www.investorideas.com/Resources/Newsletter.asp

About InvestorIdeas.com:

InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector
investing, including biotech stocks with its portal BiotechIndustryStocks.com.

Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make

recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our
sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated
by featured companies, news submissions and online advertising. AETHLON MEDICAL INC(OTC BB: AEMD )
Showcase biotech, biodefense and defense stock on Investorideas.com ( $one thousand five hundred per month, $five
thousand per month in 144 stock)Effective March 15, 2011
Aethlon Medical ( OTCBB:AEMD) :Certain of the statements herein may be forward-looking and involve risks and
uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and
other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially
different from any future results, performance, or achievements expressed or implied by the forward-looking statements.

800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com

Biodefense Stocks Snapshot; (OTCBB: AEMD), (NasdaqCM: CBLI), (NYSE Amex: PIP), (NasdaqGM: SIGA)

Point Roberts, WA - March 22, 2011 - Investorideas.com, a leader in investor sector research including biotech and biodefense stocks looks at some of the biotech stocks developing technologies and products to deal with news headlines of �radiation leaks and biological warfare�. Biodfense stocks have not been in the investor spotlight in recent years as Bioterrorism fears subsided and new issues took the forefront for Wall Street.

A major trigger for the sector are the global concerns and fears that Libyan leader, Colonel Muammar Gaddafi will potentially use biological and chemical weapons.
In a recent article on Daily Finance entitled "Inside Wall Street: Looking to the Bio-Defense Sector as Nuclear Fears Mount", notes - The sector attracted a lot of interest after 9/11 and a number of companies emerged to develop protective biodefense drugs and products. But with the waning of dark headlines about terrorist threats, investors have tended to put them on their low-priority list.
That may be about to change
Full article : http://www.dailyfinance.com/story/stock-picks/inside-wall-street-looking-to-bio-defense-sector-as-nuclear-fea/19880106/
Following 911, Project Bioshield Act was passed by Congress in 2004 calling for $5 billion for purchasing vaccines to be used in the event of a bioterrorist attack. Biotech companies continued to move forward with solutions as investors moved on to other sectors.
According to a recent article in Bioprepwatch.com, "Bioterrorism, in my view, is the most serious and likely threat to our national security, "Simon said, SNCTimes.com reports.
Full article : http://www.bioprepwatch.com/news/236579-expert-warns-of-bioterrors-ability-to-undermine-america
Chairman and CEO of Aethlon Medical, Inc.(OTCBB: AEMD) recently updated his shareholders regarding their biodfense efforts in letter March 15 th .
"As we advance our Hepatitis-C (HCV) treatment studies in India, we have also been active in our efforts to benefit from new government policies aimed at protecting U.S. civilian and military populations from bioterror and pandemic threats."
Mr. Joyce went on to say, :Earlier this year, we were honored to be invited by The Department of Health and Humans Services (HHS) to present our Hemopurifier® as a broad-spectrum platform technology to multi-agency health officials on January 12th at the Washington Convention Center. Since this presentation, our bioterror and pandemic threat initiative has led to follow-on meetings and presentations, including a formal presentation to the Biomedical Advanced Research and Development Authority (BARDA) on February 15th. "
PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, reported last month " that new pharmacokinetic data from the Company's Valortim® anthrax anti-toxin program were presented at the 9th Annual ASM Biodefense and Emerging Diseases Research Meeting, held in Washington, DC, February 6-9, 2011. The data were presented by Dr. Elizabeth Leffel, Director of Non-Clinical Sciences for PharmAthene, in a poster presentation entitled, "Pharmacokinetics of a Monoclonal Anthrax Anti-Toxin Antibody in Healthy and Infected Cynomolgus Macaques."
Biodefense Stocks Sector Snapshot

• Aethlon Medical (OTCBB: AEMD) trading at $0.14
• Cleveland BioLabs (NasdaqCM: CBLI ) trading at $7.35, up 0.19 (2.65%) 10:10AM EDT
• Emergent Biosolutions, Inc. Com (NYSE: EBS ) trading at $23.59, up 0.02 (0.08%) 10:33AM EDT
• PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, trading at $3.42, up 0.01 (0.29%) 10:31AM EDT
• Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) trading at $0.33
• Siga Technologies (NasdaqGM: SIGA ) trading at $11.83, down 0.28 (2.31%) 10:35AM EDT
• Soligenix, Inc. (OTCBB:SNGX) trading at $0.20

Research more Biodfense stocks at Investorideas.com
http://www.investorideas.com/bds/stock_list.asp
Market Snapshot

• Dow 12,027.75 -8.78 -0.07%
• NASDAQ 2,690.32 -1.77 -0.07%
• S&P 500 1,296.45 -1.93 -0.15%
• 10 Yr Bond(%) 3.3390% +0.0160
• Oil 102.45 +0.13 +0.13%
• Gold 1,426.20 0.00 0.00

Biodefense Company Snapshot
Aethlon Medical ( OTCBB:AEMD)
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
More: www.aethlonmedical.com
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
Visit the Aethlon Medical ( OTCBB:AEMD) showcase page on Investorideas.com
http://www.investorideas.com/CO/AEMD
Get added to the company's news alerts:
http://www.investorideas.com/Resources/Newsletter.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, including biotech stocks with its portal BiotechIndustryStocks.com.
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC(OTC BB: AEMD ) Showcase biotech,  biodefense and defense stock on Investorideas.com ( $one thousand five hundred per month, $five thousand per month in 144 stock)Effective March 15, 2011     
Aethlon Medical ( OTCBB:AEMD) :Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.  
800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com